Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Panel to Review Entresto’s Hypertension Indication Again on September 3
September 3, 2021
- Healthcare Spending Totals 42.2 Trillion Yen in FY2020, Showing Record Drop of 1.4 Trillion Yen: MHLW
September 2, 2021
- LDP’s COVID-19 Headquarters Calls for Guidelines on Oral Steroid Administration to Patients Recuperating at Home
September 1, 2021
- Council to Discuss Resuming Active Recommendation of HPV Vaccines: Health Minister
September 1, 2021
- Japan’s Volume-Based Generic Share Reaches 82.1% at End of FY2020, 6 Prefectures Stalling Below 80%: MHLW
September 1, 2021
- MHLW Group Launches Study for Post-Marketing Safety Measures to Boost Global Harmonization, Efficiency
September 1, 2021
- MHLW Panel Shelves Decision on Entresto’s Hypertension Use, Clears Otsuka’s Eczema Med and More
August 31, 2021
- Govt Recognizes Need to Resume HPV Vaccine Discussion: Health Minister
August 31, 2021
- MHLW, Indonesian FDA Ink MOU to Cooperate in Drug Regulations
August 31, 2021
- MHLW to Discuss Ways to Strengthen Stable Supply System of Drugs and Medical Devices: Vice Health Minister
August 30, 2021
- MHLW Discussing Mandatory Reporting System for Unstable Drug Supplies
August 30, 2021
- 500,000 of Suspended Moderna Vaccine Doses Already Used: Kono
August 30, 2021
- Govt Not Planning to Resume Active HPV Vaccine Recommendation before October: Minister
August 30, 2021
- MHLW Health Policy Bureau Seeks FY2022 Budget to Set Up Manufacturing Regime for Stable Supplies
August 27, 2021
- MHLW Health Service Bureau Seeks 468.6 Billion Yen in FY2022, 46% Rise for Infectious Disease Measures
August 27, 2021
- Reinstate Active HPV Vaccine Promotion before October: LDP League
August 27, 2021
- MHLW to Request a Record 34 Trillion Yen General Account Budget for FY2022
August 27, 2021
- MHLW Pharma Safety Bureau Seeks 246 Million Yen to Shake Off Public Distrust in Generics: FY2022 Budget Request
August 27, 2021
- MHLW Won’t Recall Moderna Vaccine Vials for Now
August 26, 2021
- Japan Approves Forxiga for CKD, Rinvoq’s Atopic Dermatitis Use and More
August 26, 2021
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…